Bidard FC, Kaklamani VG, Neven P, Streich G, et al. Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial. J Clin Oncol 2022 May 18:JCO2200338. doi: 10.1200/JCO.22.00338.
PMID: 35584336